Sigma Planning Corp
MBRX icon

Sigma Planning Corp’s Moleculin Biotech MBRX Stock Holding History

Sigma Planning Corp’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$10.3K – 1238
2023
Q4 		$10.3K Hold
2
– – ﹤0.01% 838
2023
Q3 		$7.27K Hold
2
– – ﹤0.01% 1190
2023
Q2 		$9.8K Sell
2
-6
-75% -$31.7K ﹤0.01% 1191
2023
Q1 		$55.2K Hold
8
– – ﹤0.01% 1263
2022
Q4 		$61K Hold
8
– – ﹤0.01% 1223
2022
Q3 		$61K Hold
8
– – ﹤0.01% 1211
2022
Q2 		$83K Hold
8
– – ﹤0.01% 1223
2022
Q1 		$102K Buy
8
+2
+33% +$22.9K ﹤0.01% 1305
2021
Q4 		$80K Buy
+6
New +$106K ﹤0.01% 1336

Other funds holding MBRX

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Atticus Wealth Management
Atticus Wealth Management Palm Beach Gardens, Florida $452M AUM 17.19% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $545M AUM 64.06% 1-Year Est. Return
NBC Securities
NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

Sigma Planning Corp's MBRX Position: Q1 2024 in Review

Sigma Planning Corp sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 2 shares — an estimated $10.3K sold.

Sigma Planning Corp first reported a position in MBRX in Q4 2021 and held it in 9 quarters. The position peaked at $102K in Q1 2022. 9 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

  • Sigma Planning Corp reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 2 Moleculin Biotech shares in Q1 2024, an estimated $10.3K.
  • Sigma Planning Corp first reported a position in Moleculin Biotech in Q4 2021 and held it in 9 quarters.
  • Sigma Planning Corp's Moleculin Biotech position peaked at $102K in Q1 2022.
  • 9 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on Sigma Planning Corp's 13F filing for Q1 2024, filed 2 May 2024.